Catalyst Wire Dossier Catalyst Wire Dossier

MGCD265

MGCD265 · Mirati Therapeutics
Drug timelines are a Plus or Pro feature.

6 regulatory and trial events tracked for MGCD265, covering 2015-01-08 to 2019-09-10. Get the full timeline:

Most recent: Clinical Trial Update: Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET [Phase 2]

See pricing